With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty

Core Insights - EUROAPI officially launched its innovation programs under the Health IPCEI initiative, aimed at enhancing pharmaceutical sovereignty in Europe [1][3] - The project, named "Med4Cure," is supported by the European Commission and involves collaboration with various start-ups, academic institutions, and industry partners [2][3] Company Overview - EUROAPI is a leading player in active pharmaceutical ingredients, with approximately 200 products in its portfolio and a focus on sustainable solutions [5][6] - The company operates five manufacturing sites in Europe and serves customers in over 80 countries [6] Innovation Programs - Med4Cure will co-finance R&D activities focusing on three strategic areas: corticosteroids, nanocrystals, and macrolide antibiotics [4] - The global market for EUROAPI's corticosteroids was estimated at 657 million euros in 2024 [4] Funding and Support - In June 2024, EUROAPI was selected to share up to 1 billion euros in public funding under the Health IPCEI [3] - A contractual agreement was signed in July 2025, providing up to 140 million euros in public aid under the France 2030 investment plan [3]